From Pandemic Profits to Pioneering Progress: BioNTech’s Bold New Path
BioNTech is shifting focus from its COVID-19 vaccine success to mRNA-based cancer therapies, aiming for market approvals by 2026. The fourth quarter of 2024 saw BioNTech's earnings and revenue decline,…